These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16758205)

  • 21. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.
    Dashti A; Ebrahimi M; Hadjati J; Memarnejadian A; Moazzeni SM
    Cancer Lett; 2016 Apr; 374(1):175-185. PubMed ID: 26803056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer.
    Lin T; Liang S; Meng F; Han Q; Guo C; Sun L; Chen Y; Liu Z; Yu Z; Xie H; Ding J; Fan D
    Clin Exp Immunol; 2006 May; 144(2):319-25. PubMed ID: 16634806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.
    Winter H; Hu HM; Poehlein CH; Huntzicker E; Osterholzer JJ; Bashy J; Lashley D; Lowe B; Yamada J; Alvord G; Urba WJ; Fox BA
    Immunology; 2003 Mar; 108(3):409-19. PubMed ID: 12603608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Wang Y; Liu C; Zhang L; Xia Q; Zhang Y; Wu J; Jiang C; Chen Y; Wu Y; Zha X; Yu X; Kong W
    Cancer Immunol Immunother; 2012 Oct; 61(10):1857-67. PubMed ID: 22706381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
    Kim HD; Jin JJ; Maxwell JA; Fukuchi K
    Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
    Galvin KC; Dyck L; Marshall NA; Stefanska AM; Walsh KP; Moran B; Higgins SC; Dungan LS; Mills KH
    Cancer Immunol Immunother; 2013 Jul; 62(7):1273-82. PubMed ID: 23657628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
    Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
    Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosensitization with a Bcl-2 small molecule inhibitor.
    Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
    Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
    Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
    J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo.
    Rossowska J; Pajtasz-Piasecka E; Szyda A; Krawczenko A; Zietara N; Dus D
    Oncol Rep; 2009 Jun; 21(6):1539-49. PubMed ID: 19424635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
    Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
    Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
    Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E
    Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
    DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
    J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer.
    Dai MS; Vassaux G; Xu M; You RI; Hsieh YF; Ouisse LH; Lo KY; Sytwu HK; Chao TY
    Vaccine; 2012 Nov; 30(48):6903-11. PubMed ID: 22982404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.